1989
DOI: 10.1002/ana.410260209
|View full text |Cite
|
Sign up to set email alerts
|

Peripheral pharmacokinetics of apomorphine in humans

Abstract: Apomorphine, a potent dopamine agonist, has been used in acute and chronic studies of parkinsonism and other neurological disorders. To define its peripheral pharmacokinetics, we administered apomorphine by subcutaneous injection, by subcutaneous infusion, and by intravenous infusion to 15 patients with parkinsonism and measured plasma apomorphine levels by high-performance liquid chromatography with electrochemical detection. The peak drug levels and area under the curve were closely correlated with the dose … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

5
67
1
8

Year Published

1990
1990
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 132 publications
(81 citation statements)
references
References 23 publications
5
67
1
8
Order By: Relevance
“…unlikely explanation for our findings since the available pharmacokinetic studies with apomorphine show that withinsubject variation in absorption after repeated subcutaneous administration is low (Gancher et al, 1989;Grandas & Obeso, 1989;Montastruc et al, 1991). Although the present experiments were not designed to investigate cellular mechanisms, one could hypothesize (as suggested by Costentin et al, 1975;) that tolerance to repeated injections of apomorphine involves D2 dopamine receptor desensitization.…”
Section: Discussionmentioning
confidence: 84%
“…unlikely explanation for our findings since the available pharmacokinetic studies with apomorphine show that withinsubject variation in absorption after repeated subcutaneous administration is low (Gancher et al, 1989;Grandas & Obeso, 1989;Montastruc et al, 1991). Although the present experiments were not designed to investigate cellular mechanisms, one could hypothesize (as suggested by Costentin et al, 1975;) that tolerance to repeated injections of apomorphine involves D2 dopamine receptor desensitization.…”
Section: Discussionmentioning
confidence: 84%
“…The reduc tion was marked and rapid (from .895 to 0.771 in 30 min for slow-target-gain and from 0.844 to 0.751 for fast target-gain). As mentioned previously, the pharma cokinetic data, as well as studies of motor effects in Par kinson patients, indicate that apomorphine can act within 10 min (Gancher et al 1989;Truelle et al 1975). …”
Section: Discussionmentioning
confidence: 86%
“…The pharmacokinetics of apomorphine (bolus SC in jection) in humans have been described by Gancher et al (1989). According to them, apomorphine is rapidly absorbed following subcutaneous injection, with peak plasma concentrations occurring 3 min following ad ministration.…”
Section: Pharmacokineticsmentioning
confidence: 99%
See 1 more Smart Citation
“…As no clinical motor change was supposed to occur, the moment of the second rCBF measurement was arbitrarily chosen 10 min after the s.c. injection of apomorphine. According to published data, this time was believed to correspond to the tmax of the drug (Gancher et al, 1989).…”
Section: General Proceduresmentioning
confidence: 96%